Tanvex Reports Results of TX05 (biosimilar, trastuzumab) in P-III Study for HER2-Positive Early Breast Cancer

 Tanvex Reports Results of TX05 (biosimilar, trastuzumab) in P-III Study for HER2-Positive Early Breast Cancer

Tanvex Reports Results of TX05 (biosimilar, trastuzumab) in P-III Study for HER2-Positive Early Breast Cancer

Shots:

  • The P-III study evaluates the efficacy and safety of TX05 vs Herceptin (trastuzumab) in patients with human epidermal growth factor receptor 2-positive early breast cancer
  • The 1EPs was an assessment of pCR following neoadjuvant therapy and definitive surgery in the per-protocol population
  • Results: Patients achieved pCR (48.8% vs 45.3%) in the per-protocol population

Click here ­to­ read full press release/ article | Ref: Tanvex  | Image: Tanvex

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post